AtomVie Global Radiopharma raises over $90M to complete new facility
by CM staff
AtomVie has now raised over $90M, an amount sufficient to complete the buildout and equip its 64,000 square feet purpose-built scalable facility.
HAMILTON — AtomVie Global Radiopharma (AtomVie), a global CDMO for the GMP manufacturing and worldwide distribution of radiopharmaceuticals, closed its Tranche 2 Series A financing led by its current investor, Avego Management (Avego).
Along with Tranche 1 closed in August 2022, AtomVie has now raised over $90 million, an amount sufficient to complete the buildout and equip its 64,000 square feet purpose-built scalable facility.
“We are extremely delighted to expand our relationship with Avego. This investment solidifies AtomVie’s position as a world-class CDMO for the clinical and commercial manufacturing of radiopharmaceuticals, in servicing our clients and improving the lives of thousands of patients all over the globe. With the new facility in sight for late 2024, we are excited to announce that we are currently pre-selling manufacturing capacity” said Bruno Paquin, CEO of AtomVie.
“Avego is pleased to expand its partnership with AtomVie, a collaboration that underscores our commitment to growth and innovation. AtomVie’s new facility, set to open in late 2024, will handle meaningful clinical and commercial programs with advance booking of manufacturing capacity available today” said Kevin McNeill, Partner at Avego.
AtomVie will be exhibiting at the 2023 SNMMI Annual Meeting, during which further highlights of its new facility will be shared at Booth #2024.
